James Ballenger to Placebos
This is a "connection" page, showing publications James Ballenger has written about Placebos.
Connection Strength
0.191
-
Remission rates in patients with anxiety disorders treated with paroxetine. J Clin Psychiatry. 2004 Dec; 65(12):1696-707.
Score: 0.056
-
Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998 Jan; 155(1):36-42.
Score: 0.035
-
Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Am J Psychiatry. 1997 May; 154(5):700-2.
Score: 0.033
-
Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients. J Clin Psychiatry. 1993 Jun; 54(6):224-8.
Score: 0.025
-
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry. 1988 May; 45(5):413-22.
Score: 0.018
-
A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry. 1997; 58 Suppl 11:11-8.
Score: 0.008
-
Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry. 1992 Nov; 149(11):1556-62.
Score: 0.006
-
Discontinuation of alprazolam after long-term treatment of panic-related disorders. J Clin Psychopharmacol. 1992 Oct; 12(5):352-4.
Score: 0.006
-
Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. II. Patient acceptance, side effects, and safety. Arch Gen Psychiatry. 1988 May; 45(5):423-8.
Score: 0.004